-
Mashup Score: 8
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZenecaās Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZenecaās Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial šš ā¦ā¦@GuardConsortiumā© ā¦@OncoAlertā© https://t.co/cHKC2ddkmy
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZenecaās Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial šš ā¦ā¦@GuardConsortiumā© ā¦@OncoAlertā© https://t.co/cHKC2ddkmy
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZenecaās Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial šš ā¦ā¦@GuardConsortiumā© ā¦@OncoAlertā© https://t.co/cHKC2ddkmy
-
-
Mashup Score: 40
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZenecaās Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) data were
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial šš ā¦ā¦@GuardConsortiumā© ā¦@OncoAlertā© https://t.co/cHKC2ddkmy
-
-
Mashup Score: 2Advancing Gene Editing with ePsCas9 Technology - 18 day(s) ago
Discover how ePsCas9 technology is revolutionising gene editing with enhanced precision and potential to treat rare genetic disorders.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet-
New research in @NatureComms shows how our ePsCas9 gene editing system offers greater precision. This specificity represents an important advancement in #GenomicMedicine with potential for many rare diseases. Learn more: https://t.co/GifFe3Jmsl https://t.co/BoIrZkYVYS
-
-
Mashup Score: 3Respiratory and Immunology - Our therapy areas - AstraZeneca - 29 day(s) ago
Find information about the latest scientific and clinical work conducted by AstraZeneca in Respiratory and Immunology diseases.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet-
For people living with chronic respiratory diseases such as asthma, everyday tasks can feel challenging. Learn more about ways weāre working to evolve our pipeline and improve care for these vulnerable patients: https://t.co/lSPlnCeNcX #ACAAI https://t.co/tXEdoxRf20
-
-
Mashup Score: 50
AstraZenecaās Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. 2,3 The approval by the US Food and Drug Administration (FDA) was based on positive results from the MANDARA Phase III trial published in The New England Journal of Medicine, 4 which compared the efficacy and safety of
Source: www.astrazeneca.comCategories: General Medicine News, General HCPsTweet-
Fasenra (benralizumab, an anti-IL-5 mAb) has been FDA approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA); approval based on MANDARA trial - H2H noninferior to mepolizumab at remission https://t.co/5tAPolUItK https://t.co/VHCNjACThw
-
-
Mashup Score: 60
AstraZenecaās Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. 2,3 The approval by the US Food and Drug Administration (FDA) was based on positive results from the MANDARA Phase III trial published in The New England Journal of Medicine, 4 which compared the efficacy and safety of
Source: www.astrazeneca.comCategories: General Medicine News, General HCPsTweet-
Fasenra (benralizumab, an anti-IL-5 mAb) has been FDA approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA); approval based on MANDARA trial - H2H noninferior to mepolizumab at remission https://t.co/YmpOCcivg9 https://t.co/D6VmBFJ2Uj
-
-
Mashup Score: 79
Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZenecaās Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). For the secondary endpoint of overall survival (OS),
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Important new #CLL news PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL. https://t.co/tRSPVlDmJY
-
Truqap combination in PTEN-deficient metastatic HSPC demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Ph III trial šš ā¦ā¦@GuardConsortiumā© ā¦@OncoAlertā© https://t.co/cHKC2ddkmy